GT Biopharma, Inc. — Director's Dealing 2012

May 30, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OXIS INTERNATIONAL INC (OXIS.OB)
CIK: 0000109657
Period of Report: 2012-03-01

Reporting Person: Saloff David (Director, CEO, Chairman of the Board)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-03-01	Common Stock Option	$0.04	A	26334193	Acquired	2022-03-01	Common Stock (26334193)	Direct

Footnotes

F1: David Saloff received a non-qualified stock option to purchase 26,334,193 shares of Common Stock under the Issuer's 2010 Equity Compensation Plan, in connection with his appointment as Chairman of the Board of Directors of the Company. One-third of the options vest and become exercisable immediately, and the balance vest in equal monthly installments during the three-year period following the date of grant. The options have a term of 10 years from the date of grant.